PURPOSE: The 5-year survival rate for invasive epithelial ovarian cancer is <35%. It has been suggested that common, germline genetic variation may influence survival after cancer diagnoses, which might enable the prediction of response to treatment and survival in the clinical setting. The aim of this study was to evaluate associations between common germline genetic variants in the oncogenes BRAF, ERBB2, KRAS, NMI, and PIK3CA, and survival after a diagnosis of epithelial ovarian cancer. EXPERIMENTAL DESIGN: We evaluated the association between 34 tagging single nucleotide polymorphisms and survival in 1,480 cases of invasive epithelial ovarian cancer cases from three different studies. Cox regression analysis, stratified by study, was used to estimate per rare allele hazard ratios (HR). RESULTS: The minor allele rs6944385 in BRAF was significantly associated with poor survival [HR, 1.19; 95% confidence intervals (95% CI), 1.02-1.39; P = 0.024]. The association remained after adjusting for prognostic factors (adjusted HR, 1.20; 95 CI, 1.03-1.40; P = 0.018). A haplotype of BRAF was also associated with poor survival (HR, 1.24; 95% CI, 1.02-1.51; P = 0.029) and was more significant after adjustment (HR, 1.44; 95% CI, 1.15-1.81; P = 0.001). We also found evidence of an association between a KRAS haplotype and poor survival in serous subtype (HR, 1.69; 95% CI, 1.21-2.38; P = 0.002), but this was no longer significant after adjustment. Finally, when analyses were restricted to the serous histologic subtype, the rare allele rs10842513 in KRAS, was associated with poor survival (HR, 1.40; 95% CI, 1.10-1.78; P = 0.007). CONCLUSION: Common genetic variants in the BRAF and KRAS oncogenes may be important in the prediction of survival in patients with invasive epithelial ovarian cancer.
PURPOSE: The 5-year survival rate for invasive epithelial ovarian cancer is <35%. It has been suggested that common, germline genetic variation may influence survival after cancer diagnoses, which might enable the prediction of response to treatment and survival in the clinical setting. The aim of this study was to evaluate associations between common germline genetic variants in the oncogenes BRAF, ERBB2, KRAS, NMI, and PIK3CA, and survival after a diagnosis of epithelial ovarian cancer. EXPERIMENTAL DESIGN: We evaluated the association between 34 tagging single nucleotide polymorphisms and survival in 1,480 cases of invasive epithelial ovarian cancer cases from three different studies. Cox regression analysis, stratified by study, was used to estimate per rare allele hazard ratios (HR). RESULTS: The minor allele rs6944385 in BRAF was significantly associated with poor survival [HR, 1.19; 95% confidence intervals (95% CI), 1.02-1.39; P = 0.024]. The association remained after adjusting for prognostic factors (adjusted HR, 1.20; 95 CI, 1.03-1.40; P = 0.018). A haplotype of BRAF was also associated with poor survival (HR, 1.24; 95% CI, 1.02-1.51; P = 0.029) and was more significant after adjustment (HR, 1.44; 95% CI, 1.15-1.81; P = 0.001). We also found evidence of an association between a KRAS haplotype and poor survival in serous subtype (HR, 1.69; 95% CI, 1.21-2.38; P = 0.002), but this was no longer significant after adjustment. Finally, when analyses were restricted to the serous histologic subtype, the rare allele rs10842513 in KRAS, was associated with poor survival (HR, 1.40; 95% CI, 1.10-1.78; P = 0.007). CONCLUSION: Common genetic variants in the BRAF and KRAS oncogenes may be important in the prediction of survival in patients with invasive epithelial ovarian cancer.
Authors: Ernest K Amankwah; Hui-Yi Lin; Jonathan P Tyrer; Kate Lawrenson; Joe Dennis; Ganna Chornokur; Katja K H Aben; Hoda Anton-Culver; Natalia Antonenkova; Fiona Bruinsma; Elisa V Bandera; Yukie T Bean; Matthias W Beckmann; Maria Bisogna; Line Bjorge; Natalia Bogdanova; Louise A Brinton; Angela Brooks-Wilson; Clareann H Bunker; Ralf Butzow; Ian G Campbell; Karen Carty; Zhihua Chen; Y Ann Chen; Jenny Chang-Claude; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Cezary Cybulski; Agnieszka Dansonka-Mieszkowska; Andreas du Bois; Evelyn Despierre; Ed Dicks; Jennifer A Doherty; Thilo Dörk; Matthias Dürst; Douglas F Easton; Diana M Eccles; Robert P Edwards; Arif B Ekici; Peter A Fasching; Brooke L Fridley; Yu-Tang Gao; Aleksandra Gentry-Maharaj; Graham G Giles; Rosalind Glasspool; Marc T Goodman; Jacek Gronwald; Patricia Harrington; Philipp Harter; Hanis N Hasmad; Alexander Hein; Florian Heitz; Michelle A T Hildebrandt; Peter Hillemanns; Claus K Hogdall; Estrid Hogdall; Satoyo Hosono; Edwin S Iversen; Anna Jakubowska; Allan Jensen; Bu-Tian Ji; Beth Y Karlan; Heather Jim; Melissa Kellar; Lambertus A Kiemeney; Camilla Krakstad; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Sandrina Lambrechts; Nhu D Le; Alice W Lee; Shashi Lele; Arto Leminen; Jenny Lester; Douglas A Levine; Dong Liang; Boon Kiong Lim; Jolanta Lissowska; Karen Lu; Jan Lubinski; Lene Lundvall; Leon F A G Massuger; Keitaro Matsuo; Valerie McGuire; John R McLaughlin; Ian McNeish; Usha Menon; Roger L Milne; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Heli Nevanlinna; Ursula Eilber; Kunle Odunsi; Sara H Olson; Irene Orlow; Sandra Orsulic; Rachel Palmieri Weber; James Paul; Celeste L Pearce; Tanja Pejovic; Liisa M Pelttari; Jennifer Permuth-Wey; Malcolm C Pike; Elizabeth M Poole; Harvey A Risch; Barry Rosen; Mary Anne Rossing; Joseph H Rothstein; Anja Rudolph; Ingo B Runnebaum; Iwona K Rzepecka; Helga B Salvesen; Eva Schernhammer; Ira Schwaab; Xiao-Ou Shu; Yurii B Shvetsov; Nadeem Siddiqui; Weiva Sieh; Honglin Song; Melissa C Southey; Beata Spiewankiewicz; Lara Sucheston-Campbell; Soo-Hwang Teo; Kathryn L Terry; Pamela J Thompson; Lotte Thomsen; Ingvild L Tangen; Shelley S Tworoger; Anne M van Altena; Robert A Vierkant; Ignace Vergote; Christine S Walsh; Shan Wang-Gohrke; Nicolas Wentzensen; Alice S Whittemore; Kristine G Wicklund; Lynne R Wilkens; Anna H Wu; Xifeng Wu; Yin-Ling Woo; Hannah Yang; Wei Zheng; Argyrios Ziogas; Linda E Kelemen; Andrew Berchuck; Joellen M Schildkraut; Susan J Ramus; Ellen L Goode; Alvaro N A Monteiro; Simon A Gayther; Steven A Narod; Paul D P Pharoah; Thomas A Sellers; Catherine M Phelan Journal: Genet Epidemiol Date: 2015-09-24 Impact factor: 2.135
Authors: David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Kristin L White; David N Rider; Kimberly R Kalli; Keith L Knutson; Gail P Jarvik; Ellen L Goode Journal: Cancer Causes Control Date: 2011-02-27 Impact factor: 2.506
Authors: Dong Liang; Larissa Meyer; David W Chang; Jie Lin; Xia Pu; Yuanqing Ye; Jian Gu; Xifeng Wu; Karen Lu Journal: Cancer Res Date: 2010-11-30 Impact factor: 12.701
Authors: Ellen L Goode; Georgia Chenevix-Trench; Lynn C Hartmann; Brooke L Fridley; Kimberly R Kalli; Robert A Vierkant; Melissa C Larson; Kristin L White; Gary L Keeney; Trynda N Oberg; Julie M Cunningham; Jonathan Beesley; Sharon E Johnatty; Xiaoqing Chen; Katelyn E Goodman; Sebastian M Armasu; David N Rider; Hugues Sicotte; Michele M Schmidt; Elaine A Elliott; Estrid Høgdall; Susanne Krüger Kjær; Peter A Fasching; Arif B Ekici; Diether Lambrechts; Evelyn Despierre; Claus Høgdall; Lene Lundvall; Beth Y Karlan; Jenny Gross; Robert Brown; Jeremy Chien; David J Duggan; Ya-Yu Tsai; Catherine M Phelan; Linda E Kelemen; Prema P Peethambaram; Joellen M Schildkraut; Vijayalakshmi Shridhar; Rebecca Sutphen; Fergus J Couch; Thomas A Sellers Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-01 Impact factor: 4.254
Authors: Honglin Song; Susan J Ramus; Jonathan Tyrer; Kelly L Bolton; Aleksandra Gentry-Maharaj; Eva Wozniak; Hoda Anton-Culver; Jenny Chang-Claude; Daniel W Cramer; Richard DiCioccio; Thilo Dörk; Ellen L Goode; Marc T Goodman; Joellen M Schildkraut; Thomas Sellers; Laura Baglietto; Matthias W Beckmann; Jonathan Beesley; Jan Blaakaer; Michael E Carney; Stephen Chanock; Zhihua Chen; Julie M Cunningham; Ed Dicks; Jennifer A Doherty; Matthias Dürst; Arif B Ekici; David Fenstermacher; Brooke L Fridley; Graham Giles; Martin E Gore; Immaculata De Vivo; Peter Hillemanns; Claus Hogdall; Estrid Hogdall; Edwin S Iversen; Ian J Jacobs; Anna Jakubowska; Dong Li; Jolanta Lissowska; Jan Lubiński; Galina Lurie; Valerie McGuire; John McLaughlin; Krzysztof Medrek; Patricia G Moorman; Kirsten Moysich; Steven Narod; Catherine Phelan; Carole Pye; Harvey Risch; Ingo B Runnebaum; Gianluca Severi; Melissa Southey; Daniel O Stram; Falk C Thiel; Kathryn L Terry; Ya-Yu Tsai; Shelley S Tworoger; David J Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Penelope M Webb; Lynne R Wilkens; Anna H Wu; Hannah Yang; Wendy Brewster; Argyrios Ziogas; Richard Houlston; Ian Tomlinson; Alice S Whittemore; Mary Anne Rossing; Bruce A J Ponder; Celeste Leigh Pearce; Roberta B Ness; Usha Menon; Susanne Krüger Kjaer; Jacek Gronwald; Montserrat Garcia-Closas; Peter A Fasching; Douglas F Easton; Georgia Chenevix-Trench; Andrew Berchuck; Paul D P Pharoah; Simon A Gayther Journal: Nat Genet Date: 2009-08-02 Impact factor: 38.330
Authors: Ellen L Goode; Matthew J Maurer; Thomas A Sellers; Catherine M Phelan; Kimberly R Kalli; Brooke L Fridley; Robert A Vierkant; Sebastian M Armasu; Kristin L White; Gary L Keeney; William A Cliby; David N Rider; Linda E Kelemen; Monica B Jones; Prema P Peethambaram; Johnathan M Lancaster; Janet E Olson; Joellen M Schildkraut; Julie M Cunningham; Lynn C Hartmann Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode Journal: Br J Cancer Date: 2009-09-08 Impact factor: 7.640